Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04266912CT.gov Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02595931CT.gov M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Refractory Malignant Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Berzosertib (this asset) | M.D. Anderson Cancer Center | P1/2 | CCC · 50 |
| Catequentinib | Nanfang Hospital, Southern Medical University | P3 | BB |
| Irinotecan | M.D. Anderson Cancer Center | P2 | BB |
| Durvalumab | OHSU Knight Cancer Institute | P2 | BB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Sugemalimab | Second Affiliated Hospital of Soochow University | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Nivolumab | CatalYm GmbH | P2 | BB |
| Atezolizumab | Bionoxx Inc. | P2 | B |
+42 more in the Refractory Malignant Neoplasm cohort
Other indications for Berzosertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P2 | BBB · 73 |
| Small Cell Carcinoma | — | P2 | BB · 64 |
| Fallopian Tube Carcinoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Berzosertib in Refractory Malignant Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/berzosertib-refractory-malignant-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →